SCHEMBL13638571

SCHEMBL13638571

C=C1CC(Nc2nccc(-c3ccc(C(=O)NC(C(=O)OC)c4ccc(-c5ccccc5)cc4)s3)n2)CC(C)(C)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 6/20 0.40
TEC P42680 1/20 0.36
TXK P42681 1/20 0.36
BTK Q06187 1/20 0.36
ITK Q08881 1/20 0.36
TACR3 P29371 10/20 0.35
TACR2 P21452 3/20 0.35
TSHR P16473 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
NFKB1 P19838 1/20 0.35
MTOR P42345 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471583 0.90 AKT3 (0.43) AKT3TACR3TACR2TSHRKDM4E
SCHEMBL13638504 0.88 AKT3 (0.48) AKT3TECTXKBTKITK
SCHEMBL13638565 0.88 AKT3 (0.48) AKT3TECTXKBTKITK
SCHEMBL16192783 0.83 AKT3 (0.41) AKT3TECTXKBTKITK
SCHEMBL13638465 0.83 HPGDS (0.47) AKT3TECTXKBTKITK
SCHEMBL13638295 0.82 AKT3 (0.38) AKT3TECTXKBTKITK
SCHEMBL13638474 0.81 AKT3 (0.50) AKT3TECTXKBTKITK
SCHEMBL13638466 0.80 AKT3 (0.62) AKT3TECTXKBTKITK
SCHEMBL13638569 0.79 AKT3 (0.37) AKT3TECTXKBTKITK
SCHEMBL14612850 0.79 AKT3 (0.37) AKT3TECTXKBTKITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed